Efficacy and Safety of High Dose of Lansoprazole Pretreatment in Patients with Breast Cancer Receiving Neo-Adjuvant Chemotherapy

Background: High dosage of lansoprazole (LPZ) can be used to control acidic microenvironment surrounding the cancerous cells thus improving tumor response.
 Aim: The study aimed at investigating possible antitumor efficacy and safety high dose LPZ pretreatment in patients with breast cancer (BC) receiving neo-adjuvant chemotherapy (NAC).
 Study Design: Single blinded, randomized placebo-controlled study.
 Place Duration Study: was conducted between June 2021 November 2022 Clinical Oncology Nuclear Medicine Department, Menoufia University Hospital, Egypt.
 Methodology: 66 females stage II III BC were randomly assigned into two groups; group (n=33) which started capsules 60 mg orally bid 4 days before starting NAC received placebo same regimen as group. Evaluation response done according Response Criteria Solid Tumors (RECIST, v1.1). Permeability-glycoprotein (P-gp) Ki-67 levels assessed groups after treatment. Adverse events documented graded using National Cancer Institute-Common Terminology for Events (NCI-CTCAE, v5). Trial Registration: ClinicalTrials.gov identifier: NCT04874935.
 Results: Lansoprazole showed more favorable especially within luminal B/HER2 negative subtype. non-significant decrease P-gp (P = 0.19) 0.44) compared Dyspepsia only significant adverse effect reported 0.011).
 Conclusion: However, didn't reveal a statistically anti-tumor placebo; it produced clinically important improvement translated by higher number who achieved complete response. Furthermore, during this tolerable safe.